NCT05066633View on ClinicalTrials.gov

The Efficacy and Safety of Metoprolol as add-on Treatment to Standard of Care in Preventing Cardiomyopathy in Patients With DMD

PHASE3RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

August 18, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2026

Conditions
Muscular Dystrophy, Duchenne
Interventions
DRUG

Metoprolol Succinate

Metoprolol Succinate will be in the form of tablets and will be administered orally once daily. The dose will depend on the patient's weight category. Subject should take their treatment at a consistent time each day to promote compliance. IMP will be up titrated. Every two weeks the patients will be given the higher dose of metoprolol succinate or placebo accordingly to scheme.

DRUG

Placebo

Placebo will be in the form of identical tablets and will be administered orally once daily.

Trial Locations (1)

80-211

RECRUITING

University Clinical Centre in Gdańsk, Clinic of Paediatric Cardiology and Congenital Heart Defects, Gdansk

All Listed Sponsors
lead

Medical University of Gdansk

OTHER